CendR Platform® Technology

Tumor Microenvironment-Responsive Polymeric iRGD and Doxorubicin Conjugates Reduce Spontaneous Lung Metastasis in an Orthotopic Breast Cancer Model

Nature Communications: Tumor-penetrating therapy for ß5 integrin-rich pancreas cancer

Cancer Research: Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid Malignancies

The Journal of Clinical Investigation: Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer

Advanced Drug Delivery Reviews: Tumor penetrating peptides for improved drug delivery 

Nature Communications: In vivo cation exchange in quantum dots for tumor-specific imaging

Cancer Research: Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma 

British Journal of Cancer: Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1 

Science: Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs 

Show More

CendR Platform® Technology Related

Tumour-specific activation of a tumour-blood transport improves the diagnostic accuracy of blood tumour markers in mice

Current and future immunotherapeutic approaches in pancreatic cancer treatment

Cellular collusion: cracking the code of immunosuppression and chemo resistance in PDAC

Evaluating the Therapeutic Potential of Durvalumab in Adults with Locally Advanced or Metastatic Biliary Tract Cancer: Evidence to Date

The role of TNC in atherosclerosis and drug development opportunities

RGD-Binding Integrins in Head and Neck Cancers

Molecular View on the iRGD Peptide Binding Mechanism: Implications for Integrin Activity and Selectivity Profiles

Show More

Related Oncology Publications

Clinical and Preclinical Targeting of Oncogenic Pathways in PDAC: Targeted Therapeutic Approaches for the Deadliest Cancer

Tumor-resident regulatory T cells in pancreatic cancer express the αvβ5 integrin as a targetable activation marker

A pancreatic cancer mouse model with human immunity

Drug Delivery Strategies for the Treatment of Pancreatic Cancer

Show More


CEND-1: a game changer for pancreatic cancer chemotherapy?